BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 31000444)

  • 1. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019.
    Shiohara T; Mizukawa Y
    Allergol Int; 2019 Jul; 68(3):301-308. PubMed ID: 31000444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease.
    Mizukawa Y; Hirahara K; Kano Y; Shiohara T
    J Am Acad Dermatol; 2019 Mar; 80(3):670-678.e2. PubMed ID: 30240780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS).
    Miyagawa F; Asada H
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of corticosteroid therapy on viral reactivation in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.
    Tohyama M; Hashimoto K; Oda F; Namba C; Sayama K
    J Dermatol; 2020 May; 47(5):476-482. PubMed ID: 32162382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers for cytomegalovirus reactivation before and after immunosuppressive therapy: A single-institution retrospective long-term analysis of patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic syndrome (DRESS).
    Mizukawa Y; Kimishima M; Aoyama Y; Shiohara T
    Int J Infect Dis; 2020 Nov; 100():239-246. PubMed ID: 32891735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.
    Hama N; Abe R; Gibson A; Phillips EJ
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1155-1167.e5. PubMed ID: 35176506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management.
    Shiohara T; Kano Y
    Expert Opin Drug Saf; 2017 Feb; 16(2):139-147. PubMed ID: 27936971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR).
    Kano Y; Tohyama M; Aihara M; Matsukura S; Watanabe H; Sueki H; Iijima M; Morita E; Niihara H; Asada H; Kabashima K; Azukizawa H; Hashizume H; Nagao K; Takahashi H; Abe R; Sotozono C; Kurosawa M; Aoyama Y; Chu CY; Chung WH; Shiohara T
    J Dermatol; 2015 Mar; 42(3):276-82. PubMed ID: 25623158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Induced Hypersensitivity Syndrome/Drug Reaction With Eosinophilia and Systemic Symptoms: Predictive Score and Outcomes.
    Mizukawa Y; Hama N; Miyagawa F; Takahashi H; Ogawa Y; Kurata M; Asada H; Abe R; Shiohara T
    J Allergy Clin Immunol Pract; 2023 Oct; 11(10):3169-3178.e7. PubMed ID: 37437776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions.
    Ushigome Y; Mizukawa Y; Kimishima M; Yamazaki Y; Takahashi R; Kano Y; Shiohara T
    Clin Exp Allergy; 2018 Nov; 48(11):1453-1463. PubMed ID: 30112775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.
    Mitsui Y; Shinkuma S; Nakamura-Nishimura Y; Ommori R; Ogawa K; Miyagawa F; Mori Y; Tohyama M; Asada H
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):558-565.e4. PubMed ID: 34757063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms.
    Takehara A; Aoyama Y; Kurosawa M; Shirafuji Y; Umemura H; Kamiya K; Ushigome Y; Kano Y; Shiohara T; Iwatsuki K
    Br J Dermatol; 2016 Nov; 175(5):944-952. PubMed ID: 27087170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of Human Herpes Virus-6 in the Renal Tissue of a Patient with Drug-induced Hypersensitivity Syndrome/Drug Rash with Eosinophilia and Systemic Symptoms (DIHS/DRESS).
    Hagiya H; Iwamuro M; Tanaka T; Hasegawa K; Hanayama Y; Kimura M; Otsuka F
    Intern Med; 2016; 55(13):1769-74. PubMed ID: 27374681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management.
    Shiohara T; Kano Y; Takahashi R; Ishida T; Mizukawa Y
    Chem Immunol Allergy; 2012; 97():122-38. PubMed ID: 22613858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe graft-versus-host disease-like enterocolitis accompanied with cytomegalovirus-reactivation in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.
    Takamiyagi S; Iriki H; Asahina Y; Furuichi Y; Funakoshi T; Ichikawa M; Mikami Y; Okita H; Sakiyama T; Inazumi T; Amagai M; Takahashi H
    J Dermatol; 2022 Aug; 49(8):796-799. PubMed ID: 35502510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cicatrizing Conjunctivitis in a Patient Diagnosed With Drug Reaction With Eosinophilia and Systemic Symptoms/Drug-Induced Hypersensitivity Syndrome but With Features of Stevens-Johnson Syndrome.
    Bohm KJ; Ciralsky JB; Harp JL; Bajaj S; Sippel KC
    Cornea; 2016 Jun; 35(6):888-91. PubMed ID: 27078005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis.
    Wei BM; Fox LP; Kaffenberger BH; Korman AM; Micheletti RG; Mostaghimi A; Noe MH; Rosenbach M; Shinkai K; Kwah JH; Phillips EJ; Bolognia JL; Damsky W; Nelson CA
    J Am Acad Dermatol; 2024 May; 90(5):885-908. PubMed ID: 37516359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report.
    Kim D; Kobayashi T; Voisin B; Jo JH; Sakamoto K; Jin SP; Kelly M; Pasieka HB; Naff JL; Meyerle JH; Ikpeama ID; Fahle GA; Davis FP; Rosenzweig SD; Alejo JC; Pittaluga S; Kong HH; Freeman AF; Nagao K
    Nat Med; 2020 Feb; 26(2):236-243. PubMed ID: 31959990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution.
    Ushigome Y; Kano Y; Ishida T; Hirahara K; Shiohara T
    J Am Acad Dermatol; 2013 May; 68(5):721-8. PubMed ID: 23182063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome.
    Ishida T; Kano Y; Mizukawa Y; Shiohara T
    Allergy; 2014 Jun; 69(6):798-805. PubMed ID: 24749495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.